The increasing resistance of *Acinetobacter baumannii* to antimicrobial drugs, including carbapenems ([@R1]*--*[@R3]), and resistance to desiccation and disinfectants ([@R4]) contribute to its persistence in hospital environments and propensity to cause outbreaks ([@R5]*,*[@R6]). In February 2006, a patient colonized with a multidrug-resistant *A. baumannii* strain was admitted to the medical--surgical intensive care unit (ICU) of a hospital in Madrid, Spain. This strain then spread rapidly, persisted for [\>]{.ul}30 months, and caused a large outbreak in the hospital. We report details of this outbreak.

The Study
=========

We conducted a retrospective longitudinal study at 12 de Octubre University Hospital, Madrid, Spain, of patients colonized/infected with *A. baumannii* during January 2006--May 2008. We also conducted a cohort study of patients with *A. baumannii* bacteremia during January 2002--May 2008.

MICs of drugs were confirmed by using Etest strips (AB Biodisk, Solna, Sweden) according to the manufacturer's criteria. Multidrug-resistant (MDR) phenotypes were defined as resistance to 5 classes of drugs: antipseudomonal cephalosporins (ceftazidime, cefepime), carbapenems (imipenem, meropenem), piperacillin/tazobactam, fluoroquinolones, and aminoglycosides (gentamicin, tobramycin, amikacin). Isolates were classified on the basis of antimicrobial susceptibility patterns: antibiotype 1, MDR isolates; antibiotype 2, isolates resistant to carbapenems but not MDR; and antibiotype 3, isolates susceptible to carbapenems. Colonization was defined as isolation of *A. baumannii* from [\>]{.ul}1 clinical specimen in the absence of clinical symptoms consistent with infection. Bacteremia was determined by application of criteria proposed by the Centers for Disease Control and Prevention (Atlanta, GA, USA) ([@R7]).

Clonal relatedness between clinical isolates was determined by using pulsed-field gel electrophoresis (PFGE) and the CHEF DRIII system (Bio-Rad Laboratories, Hercules, CA, USA) according to reported techniques ([@R8]). Migration of DNA fragments was normalized, and computer-assisted analysis of PFGE patterns was conducted by using Bionumerics software (Applied Maths, Sint-Martens-Latem, Belgium). Multilocus sequence typing (MLST) was performed according to published protocols ([@R9]). Isolates were assigned to a sequence type according to the allelic profiles database (<http://pubmlst.org/abaumannii/>). Univariate analysis was performed by using the *t* test for continuous variables and the χ^2^ or Fisher exact tests for categorical variables. Adjusted odds ratios (ORs) were calculated by using logistic regression analysis. Data were analyzed by using SPSS software (SPSS Inc., Chicago, IL, USA). A p value \<0.05 was considered significant.

During January 2006--May 2008, a total of 377 patients were colonized/infected with *A. baumannii.* Mean age of the patients was 57 years and 63.4% were men. Patients were hospitalized mostly in ICUs (184, 48.8%), and in surgical (100, 26.5%), medical (85, 22.5%), and pediatric (8, 2.1%) wards. A total of 76.9% (290/377) of the isolates were antibiotype 1, 9.0% (34/377) were antibiotype 2, and 14.1% (53/377) were antibiotype 3. Temporal distribution of cases is shown in [Figure 1](#F1){ref-type="fig"}, panel A. Bacterial isolates of antibiotype 1 were assigned to the major clonal type (clone AbH12O-A2) by PFGE. Of 290 patients with *A. baumannii* antibiotype 1 isolates (clone AbH12O-A2), 165 patients were infected (57%) and 125 (43%) were colonized.

![Temporal distribution of patients with *Acinetobacter baumannii* infections, Spain. A) Patients colonized/infected with *A. baumannii* classified by antibiotype. Arrows indicate times of intensification of infection control measures. The medical--surgical intensive care unit at Octubre University Hospital, Madrid, Spain, was refurbished in July 2007. B) Annual incidence of *A. baumannii* bacteremia. ABCA, *A. baumannii* clone A or AbH12O-A2; ABNCA: *A. baumannii* nonclone A.](09-1866-F1){#F1}

MLST analysis of 3 isolates belonging to clone AbH12O-A2 was performed to determine the relationship between these isolates and other described strains. The 3 isolates showed the same allelic profile of 7 housekeeping genes (allele no. in brackets; *gltA* \[1\], *gyrB* \[18\], *gdhB* \[18\], *recA* \[10\], *cpn60* \[14\], *gpi* \[29\], and *rpoD* \[18\]) and were identified as sequence type 56 according to the MLST database (<http://pubmlst.org/abaumannii/>).

*A. baumannii* clone AbH12O-A2, which showed a broad antimicrobial drug-resistance profile, resistance to carbapenems, and susceptibility only to tigecycline and colistin, was present throughout the entire 30-month study and peaked several times until the medical--surgical ICU was refurbished in July 2007. The number of new case-patients with clone AbH12O-A2 then decreased; [\<]{.ul}3 cases/month were observed during October 2007--February 2008 ([Figure 1](#F1){ref-type="fig"}, panel A).

Annual incidence of *A. baumannii* bacteremia increased from 0.03 episodes/100,000 bed days in 2002 to 1.1/100,000 bed days in 2007 ([Figure 1](#F1){ref-type="fig"}, panel B), which coincided with the outbreak peak caused by clone AbH12O-A2. Clinical features of patients with *A. baumannii* bacteremia are shown in [Table 1](#T1){ref-type="table"}. Multivariate analysis of bacteremia caused by clone AbH12O-A2 and nonclone AbH12O-A2 showed that variables independently associated with AbH12O-A2 bacteremia were hospitalization in ICUs (OR 3.48, 95% confidence interval \[CI\] 1.23--9.54), exposure to [\>]{.ul}3 antimicrobial drugs (OR 3.13, 95% CI 1.12--8.76), and ventilator-associated pneumonia as the source of bacteremia (OR 8.35, 95% CI 1.12--8.76).

###### Clinical characteristic of patients with *Acinetobacter baumannii* bacteremia, Spain\*

  Characteristic                                                    Clone ABCA, n = 65   Clone ABNCA, n = 29   p value   OR (95% CI)
  ----------------------------------------------------------------- -------------------- --------------------- --------- --------------------
  Age, y                                                            57.5 ± 14.2          58.7 ± 19.6           0.730     NA
  Male sex                                                          50 (76.9)            21 (72.4)             0.639     1.27 (0.47--3.45)
  Concurrent conditions                                                                                                  
  Immunosuppression                                                 12 (18.5)            6 (20.7)              0.800     0.87 (0.29--2.60)
  Solid tumor                                                       16 (24.6)            6 (20.7)              0.678     1.25 (0.43--3.62)
  Hematologic malignancy                                            1 (1.5)              1 (3.4)               0.553     0.44 (0.03--7.25)
  Diabetes mellitus                                                 9 (13.8)             9 (31.0)              0.050     0.36 (0.12--1.03)
  Liver cirrhosis                                                   11 (16.9)            3 (10.3)              0.408     1.76 (0.45--6.88)
  Heart failure                                                     4 (6.2)              3 (10.3)              0.475     0.57 (0.12--2.72)
  Chronic obstructive pulmonary disease                             7 (10.8)             3 (10.3)              0.951     1.05 (0.25--4.37)
  Liver transplant                                                  15 (23.1)            7 (24.1)              0.911     0.94 (0.34--2.64)
  Duration of hospitalization before *A. baumannii* bacteremia, d   34.8 ± 36.1          23.9 ± 27.5           0.150     NA
  Hospital location                                                                                                      
  Intensive care unit                                               41 (63.1)            9 (31.0)              0.004     3.80 (1.50--9.66)
  Medical ward                                                      6 (9.2)              12 (41.4)             0.001     0.14 (0.05--0.44)
  Surgical ward                                                     18 (27.7)            8 (27.6)              0.992     1.00 (0.38--2.68)
  Source of bacteremia                                                                                                   
  Catheter-related infection                                        25 (38.5)            9 (31.0)              0.489     1.39 (0.54--3.52)
  Pneumonia associated with mechanical ventilation                  18 (27.7)            1 (3.4)               0.006     10.72 (1.36--84.8)
  None (primary bacteremia)                                         12 (18.5)            14 (48.3)             0.003     0.24 (0.09--0.63)
  Intraabdominal infection                                          7 (10.8)             2 (6.9)               0.716     1.62 (0.32--8.37)
  Urinary tract infection                                           3 (4.6)              2 (6.9)               0.642     0.65 (0.10--4.13)
  Other                                                             0                    1 (3.4)               0.309     3.32 (2.43--4.52)
  Carbapenem resistance                                             65 (100.0)           7 (24.1)              0.001     0.09 (0.50--0.20)
  Prior colonization with *A. baumannii*                            43/62 (69.4)         1/17 (5.9)            0.001     36.21(4.47--293.1)
  Antimicrobial drugs used                                                                                               
  Cephalosporin                                                     7/62 (11.3)          3/29 (10.3)           0.893     1.10 (0.26--4.61)
  Piperacillin/tazobactam                                           21/62 (33.9)         4/29 (13.8)           0.046     3.20 (0.98--10.41)
  Fluorquinolone                                                    24/62 (38.7)         9/29 (31.0)           0.478     1.40 (0.54--3.59)
  Glycopeptide                                                      44/62 (71.0)         12/29 (41.4)          0.007     3.46 (1.38--8.69)
  Aminoglycoside                                                    17/62 (27.4)         8/29 (27.6)           0.987     0.99 (0.37--2.66)
  Carbapenem                                                        41/62 (66.1)         11/29 (37.9)          0.011     3.20 (1.28--7.99)
  [\>]{.ul}3 drugs                                                  36/62 (58.1)         8/29 (27.6)           0.007     3.63 (1.40--9.47)
  Invasive procedure or device                                                                                           
  Central venous catheter†                                          51/64 (79.7)         15/29 (51.7)          0.006     3.66 (1.42--9.46)
  Surgical procedure‡                                               33/64 (51.6)         11/29 (37.9)          0.223     1.74 (0.71--4.27)
  Mechanical ventilation†                                           49/64 (76.6)         14/29 (48.3)          0.007     3.50 (1.38--8.87)
  Duration of hospitalization after *A. baumannii* bacteremia, d    46.6 ± 72.9          20.5 ± 21.2           0.050     NA
  Died during hospitalization                                       35 (53.8)            9 (31.0)              0.041     2.59 (1.03--6.54)

\*Values are mean ± SD or no. (%) except as indicated. Clone ABCA, *A. baumannii* clone A (AbH12O-A2); ABNCA, *A. baumannii* nonclone A; OR, odds ratio; CI, confidence interval; NA, not applicable. †Week before bacteremia. ‡Month before bacteremia.

Plasmid pMMA2 (GenBank accession no. GQ377752), which was isolated from the clone causing the outbreak (AbH12O-A2), harbored a *bla*~OXA-24~ gene ([@R10]) coding for carbapenemase OXA-24 (also called OXA-40) as described ([@R11]). Four additional clones were detected during the outbreak (AbH12O-D, AbH12O-CU1, AbH12O-CU2, and AbH12O -CU3), which harbored plasmids pMMD, pMMCU1, pMMCU2, and pMMCU3, respectively (GenBank accession nos. GQ904226, GQ342610, GQ476987, and GQ904227). Carbapenem resistance in all clones was linked to a plasmid harboring the *bla*~OXA-24~ gene flanked by XerC/XerD-like recombination sites ([@R11]). Comparative analysis among plasmid sequences showed different patterns and coding regions. All plasmids, including pMMA2, harbored the *bla*~OXA-24~ gene as part of a DNA module flanked by XerC/XerD-like sites, which suggested that these sites are involved in mobilization of DNA containing the *bla* ~OXA-24~ gene by site-specific recombination ([@R11]).

Two genes with a putative role in virulence were detected in plasmids from clones AbH12O-A2 and AbH12O-CU3 upstream of *bla*~OXA-24~: a septicolysin-like gene coding for a pore-forming toxin ([@R12]), and a TonB-dependent receptor gene coding for an outer membrane protein involved in iron uptake and virulence ([@R13]*--*[@R15]). Insertion sequence 4, which provided an additional promoter sequence, was detected upstream from the septicolysin gene in plasmid pMMA2; this sequence was absent in plasmid pMMCU3 ([Figure 2](#F2){ref-type="fig"}). Two nucleotide changes detected in promoter regions provided an additional promoter region for the TonB-dependent receptor gene in plasmid pMMA2.

![Nucleotide sequence of the region between the septicolysin and Ton-B dependent receptor genes of *Acinetobacter baumannii* in plasmids pMMA2 and pMMCU3 from clone AbH12O-A2 (upper panel) and AbH12O-CU3 (lower panel), respectively. Integrated insertion sequence 4 (IS4) (red letters) provided a new promoter sequence for septicolysin in plasmid pMMA2 from clone AbH12O-A2. Upper case letters indicate amino acids. IRL, inverted repeated left sequence; IRR, inverted repeated right sequence from IS4; Stop, stop (termination) codon.](09-1866-F2){#F2}

Real-time PCR ([Table 2](#T2){ref-type="table"}) was performed to analyze expression of septicolysin and TonB-dependent receptor genes in clones AbH12O-A2 and AbH12O-CU3. Expression of septicolysin in clone AbH12O-A2 was 2.1× times higher than that of clone AbH12O-CU3. Conversely, the TonB-dependent receptor was also overexpressed in clone AbH12O-A2 (1.8× higher than in clone AbH12O-CU3).

###### Oligonucleotides used in real-time reverse transcription PCRs for *Acinetobacter baumannii*, Spain\*

  Primer              Gene                       Sequence, 5′ → 3′
  ------------------- -------------------------- -------------------------
  TonB-Forw           TonB-dependent receptor    GGACTGGTGATAAAGCACTAT
  TonB-Rev            TonB-dependent receptor    GCCGCATAGAGTTATCACATC
  Septicolysin-Forw   Septicolysin               CACCATCTTGTACCAATACATTT
  Septicolysin-Rev    Septicolysin               GAAATTAGCAGAAGCTCTCTTAC
  rpoB-Forw           RNA polymerase subunit B   CAGCCGCGAYCAGGTTGACTACA
  rpoB-Rev            RNA polymerase subunit B   GACGCACCGCAGGATACCACCTG
  gyrB-Forw           DNA gyrase subunit B       AAGTGAGGTAAAACCAGCGGTA
  gyrB-Rev            DNA gyrase subunit B       AATCTTGCCTGCAATTGATTTT

\*Forw, forward; rev, reverse.

Conclusions
===========

Outbreaks of MDR *A. baumannii* have been demonstrated in many studies ([@R1]*,*[@R2]*,*[@R5]). We report a large outbreak during 2006--2008 that persisted for [\>]{.ul}30 months. The AbH12O-A2 strain was pathogenic and caused 65 cases of bacteremia.

Clone AbH12O-A2 had unique characteristics. First, it was an MDR (including carbapenems) clone (ST56), susceptible only to tigecycline and colistin. Second, it harbored a carbapenemase *bla*~OXA-24~ gene, flanked by XerC/XerD binding sites located on a plasmid, which probably spread to other *Acinetobacter* clones by a Xer recombination system ([@R11]). Third, this clone overexpressed 2 putative virulence factors, septicolysin and TonB-dependent receptor.

The septicolysin gene showed 2× overexpression caused by insertion of IS4, which provided an additional promoter. Although the exact role of septicolysin is unknown, it has been designated a cholesterol-dependent cytolysin, which has been reported to be produced by pathogenic bacteria such as *Clostridium perfringens*, *Bacillus anthracis*, and *Streptococcus pneumoniae* to aid invasion of tissues or cells ([@R12]).

The protein produced by the TonB-dependent receptor gene has been associated with virulence and iron uptake in *A. baumannii* ([@R13]) and may be involved in survival of bacteria in the lungs and blood. This characteristic may explain the large rate of bacteremia caused by clone AbH12O-A2. Thus, clinicians should be alert for the MDR ST56 *A. baumannii* clone because its spread would have serious health consequences.
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